Home Forums Melanoma Diagnosis: Stage IV BMS PD1 Trial possibly recruiting Reply To: BMS PD1 Trial possibly recruiting


I found that trial is not recruiting anymore at the University of Chicago. I don’t know about the other places. I asked the contact at the University of Chicago about another trial: Anti-LAG with Nivolumab (Nivolumab given in 2 of 3 arms) NCT01968109, and he said that trial will begin recruiting in mid-February. Interestingly (and frustratingly) prior ipi is an exclusion even though it is not used in the trial. There is an exclusion reference to “Any prior exposure to immune cell modulating antibody regimens except as described…” which I guess covers ipi; however, prior anti-PD-1 and anti-PDL are allowed in two of the parts of the trial if the patient was unresponsive and progressed on those treatments. Interpretation is difficult but probably some response followed by progression would not be allowed.